NANJING, China, Aug. 5 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE:SCR), a leading manufacturer and supplier of branded generic and innovative anti-cancer pharmaceuticals in China, announced today that it intends to release its 2009 second quarter results on Monday, August 17, 2009, after the market closes in the United States. Simcere's chief executive officer, Jinsheng Ren, and chief financial officer, Frank Zhigang Zhao, will host an earnings conference call to discuss the company's 2009 second quarter results on Tuesday, August 18, at 8 a.m. ET (Tuesday, August 18, at 8 p.m. Beijing/Hong Kong time). To access the conference call, please dial: United States toll-free: +1.866.510.0705 International: +1.617.597.5363 North China toll-free: 10.800.152.1490 South China toll-free: 10.800.130.0399 China toll free / Netcom: 10 800 852 1490 Hong Kong: +852.3002.1672 Please ask to be connected to Q2 2009 Simcere Pharmaceutical Group Earnings Conference Call and provide the following passcode: 78992895. Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the "Investor Relations" section of the company's web site at http://www.simcere.com/ . Following the earnings conference call, an archive of the call will be available by dialing: United States toll-free: +1.888.286.8010 International: +1.617.801.6888 The passcode for replay participants is: 77592594. The telephone replay also will be archived on the "Investor Relations" section of the company's web site for seven days following the earnings announcement. About Simcere Pharmaceutical Group Simcere Pharmaceutical Group (NYSE:SCRNYSE:Simcere) is a leading manufacturer and supplier of branded generic and innovative pharmaceuticals in China. In recent years, Simcere has been focusing its strategy on the development of innovative pharmaceuticals and first-to-market generics, and has introduced an innovative anti-cancer medication Endu, a first-to-market medication Sinofuan, and first-to-market generics such as Bicun and Anxin. Simcere manufactures and sells antibiotics, anti-cancer medication and stroke management medication. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, osteoporosis and infectious diseases. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com/ . DATASOURCE: Simcere Pharmaceutical Group CONTACT: Investor and media inquiries: ; In Nanjing: Frank Zhigang Zhao, Chief Financial Officer, Simcere Pharmaceutical Group at +86-25-8556-6666 x8818; In Beijing: Ruirui Jiang, Brunswick Group at +86-10-6566-2256; In Hong Kong: Joseph Lo Chi-Lun, Brunswick Group at +852-3512-5000; In New York: Kate Tellier, Brunswick Group LLC at +1-212-333-3810 Web Site: http://www.simcere.com/

Copyright